



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/822,873	04/13/2004	Daniel R. Henderson	CELL-004CON2	3173

29585 7590 03/31/2006

DLA PIPER RUDNICK GRAY CARY US LLP  
153 TOWNSEND STREET  
SUITE 800  
SAN FRANCISCO, CA 94107-1907

EXAMINER

WHITEMAN, BRIAN A

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 03/31/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)	
	10/822,873	HENDERSON ET AL.	
	Examiner	Art Unit	
	Brian Whiteman	1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 12 December 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 61-98 is/are pending in the application.
- 4a) Of the above claim(s) 65,66,74,75,85 and 86 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 61-64,66-73,76-84 and 87-98 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 13 April 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                       |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)               | Paper No(s)/Mail Date. _____  |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)   |
| Paper No(s)/Mail Date <u>10/18/04</u> .  | 6) <input checked="" type="checkbox"/> Other: <u>Notice to comply w/ Seq.</u> |

<b>Notice to Comply</b>	<b>Application No.</b> 10/822,873	<b>Applicant(s)</b> HENDERSON et al.	
	<b>Examiner</b> B. Whiteman	<b>Art Unit</b> 1635	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Figures 14-19 contains sequences that are not listed in the CRF.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the specification.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

## **DETAILED ACTION**

### **Non-Final Rejection**

Claims 61-98 are pending.

### ***Election/Restrictions***

Applicant's election with traverse of Group V (claims 73-77, 81, 82, and 86-92, now claims 79-84 and 87-98) in the reply filed on 12/12/05 is acknowledged. The traversal is on the ground(s) that it would not be an undue burden on the examiner to search Group II and Group V because conducting a search of Group V the examiner has also inherently searched Group II. This is found persuasive and Group II will be rejoined with the elected invention. However, applicants did not address the restriction requirement between the other groups. Thus, groups I, III, IV, and VI remains for the reasons of record

The requirement is still deemed proper and is therefore made FINAL.

In the response to the election filed on 12/12/05, Applicants did not elect a species for Group V. However, applicants elected the species PSA-TRE in paper filed on 3/2/06.

Claims 65, 66, 85, and 86 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 12/12/05.

PB-TRE, hKLK2-TRE, AFP-TRE, CEA-TRE, and MUC-TRE in claim 83, PB-TRE and hKLK2-TRE in claim 72, and claims 74 and 75 are withdrawn from further consideration

pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 3/2/06.

***Priority***

The status of the parent application in the cross-reference on page 1 of the instant specification need updated.

Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows:

The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

The disclosure of the prior-filed application, Application No. 08/495,034, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application.

Instant claims 61, 62, 69-71, 79-84 and 89-98 are not supported by application '034 because the application does not provide sufficient written description for a genus of transcription regulatory element (TRE). In addition, the application does not provide sufficient

description of an adenovirus death protein (SEQ ID NO: 10 or 11) in claims 69-71 and 89-91 or the adenovirus comprising a second TRE as set forth in claims 79-84 and 89-98.

“It is not sufficient for purposes of the written description requirement of Section 112 that the disclosure, when combined with the knowledge in the art, would lead one to speculate as to modifications that the inventor might have envisioned, but failed to disclose.” *Lockwood v. American Airlines Inc.*, 41 USPQ2d 1961, 1966 (CAFC 1997).

Application ‘034 only provides sufficient description for a prostate specific antigen TRE and the adenovirus vector comprising a transgene.

The disclosure of the prior-filed application, Application No. 08/866,753, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application.

Instant claims 61, 62, 69-71, 79-84 and 89-98 are not supported by application ‘034 because the application does not provide sufficient written description for a genus of transcription regulatory element (TRE). In addition, the application does not provide sufficient description of an adenovirus death protein (SEQ ID NO: 10 or 11) in claims 69-71 and 89-91 or the adenovirus comprising a second TRE as set forth in claims 79-84 and 89-98. See *Lockwood v. American Airlines Inc.*, 41 USPQ2d 1961, 1966 (CAFC 1997).

Application ‘753 only provides sufficient description for a prostate specific antigen TRE and the adenovirus vector comprising a transgene.

Thus, instant claims 61, 62, 69-71, 79-84, 89-98 only have priority to application 09/151,376 filed on 9/10/98.

### *Specification*

The disclosure is objected to because of the following informalities: This application contains sequence disclosures that are encompassed by the definition for nucleotide sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequence Disclosures.

The sequences listed in Figures 14-19 of the instant specification are missing a corresponding SEQ ID NO:. It is not apparent if the sequences are located in the CRF.

A complete response to the instant office action should include a response to the Notice to Comply Letter.

Appropriate correction is required.

### *Claim Rejections - 35 USC § 112*

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claims 68, 77, 78, 97 and 98 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 68 recites the limitation "said cytokine" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim.

The term "nucleotides –5322 and –3739 relative to the transcription start site of prostate specific antigen" in claims and 77 and 97 is a relative term, which renders the claims indefinite. The term "nucleotides –5322 and –3739 relative to the transcription start site of prostate specific antigen " is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The metes and bound of the term are undefined because there are several types of prostate specific antigen gene with different nucleotide lengths.

The term "nucleotides –540 and +8 relative to the transcription start site of prostate specific antigen" in claims 78 and 98 is a relative term, which renders the claims indefinite. The term "nucleotides –540 and +8 relative to the transcription start site of prostate specific antigen " is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The metes and bound of the term are undefined because there are several types of prostate specific antigen genes each with different nucleotide lengths.

### *Claim Rejections - 35 USC § 102*

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 61-64, 67, 72, 73 and 76 are rejected under 35 U.S.C. 102(e) as being anticipated by Gregory et al (3). Gregory teaches a method of treating mammalian cancer cells, comprising administering a replication competent adenoviral vector comprising a therapeutic gene and a disease specific gene regulatory region operationally linked to at least one replication gene wherein the cancer cells activate the tumor specific gene regulatory region causing the adenoviral to replicate (page 7, claim 1). Furthermore, Gregory teaches using the alpha-fetoprotein promoter/enhancer, the carcinoembryonic antigen promoter/enhancer or the tyrosinase promoter/enhancer (page 7, claims 2, 4, 9, respectively). Gregory further teaches that the replication gene used for making the vector in the method described above is a viral E1 genes, E2 gene, or E4 gene (pages 2 and 7, claims 16-18).

Claims 61 and 62 are rejected under 35 U.S.C. 102(b) as being anticipated by Hallenbeck et al., (71). Hallenbeck teaches a tissue-specific replication-conditional adenovirus vector comprising a heterologous tissue-specific transcriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication, wherein said coding region is selected from the group consisting of E1a, E1b, E2a, E2b, and E4 coding regions (pages 3, 5-9, 15-17, 31-39, and 46-50). Hallenbeck further teaches that the promoter in the vector is selected from the group consisting of alpha-fetoprotein, DF3, tyrosinase, CEA, surfactant protein, and ErbB2 promoters (page 10). An isolated tumor cell containing a tissue-specific replicational conditional adenovirus vector, said vector comprising a heterologous tissue-specific transcriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector, wherein said transcriptional regulatory sequence functions in said cell

Art Unit: 1635

so that replication of the vector occurs in said cell, wherein said coding region is selected from the group consisting of E1a, E1b, and E2 and E4 coding regions (pages 46-50). A producer cell is provided which contains a virion produced in the cell by replication in the cell of the replication-conditional adenoviral vectors (pages 28, 29 and 46-50).

### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

Art Unit: 1635

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 61, 64, 67, and 68 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gregory et al. (3) taken with Srivastava (US 5,252,479). Gregory teaches a method of treating mammalian cancer cells, comprising administering a replication competent adenoviral vector comprising a therapeutic gene and a disease specific gene regulatory region operationally linked to at least one replication gene wherein the cancer cells activate the tumor specific gene regulatory region causing the adenoviral to replicate (page 7, claim 1). Furthermore, Gregory teaches using the alpha-fetoprotein promoter/enhancer, the carcinoembryonic antigen promoter/enhancer or the tyrosinase promoter/enhancer (page 7, claims 2, 4, 9, respectively). Gregory further teaches that the replication gene used for making the vector in the method described above is a viral E1 genes, E2 gene, or E4 gene (pages 2 and 7, claims 16-18). Gregory teaches using a foreign gene encoding a cytokine in the adenovirus vector (pages 2 and 4-5). However, Gregory does not specifically teach using the cytokine GM-CSF.

However, at the time the invention was made, Srivastava teaches delivering a vector comprising a gene encoding GM-CSF to treat cancer in a subject (column 6).

It would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made to combine the teaching of Gregory taken with Srivastava, namely to use the cytokine GM-CSF in the method taught by Gregory. One of ordinary skill in the art would have been motivated to combine the teaching because GM-CSF is a cytokine that can be used in killing tumor cells.

Therefore the invention as a whole would have been *prima facie* obvious to one ordinary skill in the art at the time the invention was made.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 61, 62, 63, 72, 76, 77 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 12 of U.S. Patent No. 5,698,443. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of ‘443 are both directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a prostate specific antigen transcriptional regulatory element operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4.

Claims 61, 62, 63, 64, 72, 76, 79, 81, 83, 84, 89, 92, 93, and 96 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 10 and 29-31 of U.S. Patent No. 6,676,935. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of '935 are both directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a prostate specific antigen transcriptional regulatory element (PSA-TRE) operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4. The claims of '935, further recite using two TREs in the adenoviral vector, wherein both TREs are PSA-TRE. Furthermore, the claims of '935 teach operably linking a transgene encoding an adenovirus death protein to a TRE.

Claims 61, 62, 69-71, 79, and 89-91 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 17-20, 30-32, 44-48, and 51-54 of U.S. Patent No. 6,197,293. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of '293 are both directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a prostate specific antigen transcriptional regulatory element operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4. The claims of '293 further recite an adenovirus death gene under the control of a TRE. The claims do not specifically recite the adenovirus death gene encoding SEQ ID NO: 10 or 11 of instant application. However, the definition of an adenovirus death gene is in the specification of '293 defines the adenovirus death gene as encoding SEQ ID NO: 10 or 11. See column 27. Thus, it would have been obvious to one of ordinary skill in the art to use a gene

encoding SEQ ID NO: 10 or 11 as the adenovirus gene because the sequences were readily available saving time from cloning the adenovirus death protein.

Claims 61, 62, 79, 80, 82, and 92-95 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 15, 16, 24, and 25 of U.S. Patent No. 6,436,394. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of '394 are both are directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising two transcriptional regulatory element TRE, wherein one TRE is operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4.

Claims 61 and 62 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 7,011,976. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of '976 are both are directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4.

Claims 61, 62, and 69-71 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 34-63 of U.S. Patent No. 6,254,862. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of '862 are both are directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a

Art Unit: 1635

transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4.

Claims 61 and 62 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 21 of U.S. Patent No. 6,585,968. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of '968 are both directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4.

Claims 61, 62, 64, 67-69, 71, 79, 81, 82, 84, 87-89, and 91 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-4, 8-15, and 17-19 of U.S. Patent No. 6,991,935. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4. The claims of '935 are directed to adenovirus comprising a transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication selected from the group consisting of E1A, E1B and E4 uses for selective cytolysis of cells. Thus, the claims '935 are an obvious variant of the instant claims.

Claims 61-63, 73, and 76-78 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21-32 of U.S. Patent No. 5,871,726.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both are directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication.

Claims are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims of U.S. Patent No. in view of.

Claims 61, 62, 79, and 80 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 82-89 of copending Application No. 11/267,275. Although the conflicting claims are not identical, they are not patentably distinct from each other because both set of claims are directed to a method for selective cytolysis of a target cell comprising administering to the cell an adenovirus comprising a transcriptional regulatory element TRE, wherein the TRE is operably linked to an adenoviral gene essential for replication.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Furthermore, the following serial numbers of co-pending applications contain claims in which an obviousness-type double patenting rejection would be applied:

11/166,234

11/153,458

It is Applicants' burden to file appropriate terminal disclaimers for all relevant applications listed above. Furthermore, if Applicants are aware of any pending applications or patents, which are not listed above, it is Applicants' duty to disclose these applications or patents, and to submit an appropriate terminal disclaimer over these applications or patents as pertinent to the instant invention.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 61 and 62 are directed to an invention not patentably distinct from claim 21 of commonly assigned US Patent 6,585,968. Specifically, for the reasons set forth under the obvious double patenting rejection.

Claims 61 and 62 are directed to an invention not patentably distinct from claims 17-20, 30-32, 44-48, and 51-54 of commonly assigned US Patent 6,197,293. Specifically, for the reasons set forth under the obvious double patenting rejection.

Claims 61 and 62 are directed to an invention not patentably distinct from claims 1-10 of commonly assigned US Patent 7,011,976. Specifically, for the reasons set forth under the obvious double patenting rejection.

Claims 61, 62, 79, 80, 82, and 92-95 are directed to an invention not patentably distinct from claims 15, 16, and 24-25 of commonly assigned US Patent 6,436,394. Specifically, for the reasons set forth under the obvious double patenting rejection.

Claims 61, 62, and 69-71 are directed to an invention not patentably distinct from claims 34-63 of commonly assigned US Patent 6,254,862. Specifically, for the reasons set forth under the obvious double patenting rejection.

Claims 61, 62, 64, 67-69, 71, 79, 81, 82, 84, 87-89, and 91 are directed to an invention not patentably distinct from claims 1-4, 8-15, and 17-19 of commonly assigned US Patent 6,991,935. Specifically, for the reasons set forth under the obvious double patenting rejection.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned US Patent, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764.

Art Unit: 1635

The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, acting SPE – Art Unit 1635, can be reached at (571) 272-0811.


Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Brian Whiteman  
Patent Examiner, Group 1635



**BRIAN WHITEMAN**  
**PATENT EXAMINER**